Neurim and Flynn have decided to strengthen their collaboration: Flynn has been marketing Neurim's Circadin®, indicated to treat the elderly for primary insomnia, in UK and Ireland since 2012. Neurim's PedPRM, targeted to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases, is expected to be the first sleep drug approved for children.
"Flynn is a perfect match to the strategy of our paediatric sleep drug. We have trust in their ability to bring this essential treatment to children who suffer severely from sleep problems," said Nava Zisapel, CEO of Neurim Pharmaceuticals. "We are in the midst of discussions with potential partners to allow more children to benefit from this treatment in additional markets."
"We are delighted to further build and extend our Neurim partnership - their development and clinical expertise have heralded important progress in the understanding and management of insomnia," said David Fakes, CEO of Flynn Pharma.
PedPRM is a response to the unmet clinical need in the field of paediatric insomnia, specifically developed to address main concerns in children with ASD and neurogenetic diseases. PedPRM is an age-appropriate formulation designed for populations with swallowing difficulties.
PedPRM completed a Phase III study, under EU-PIP and US-FDA IND, showing positive top-line results. PedPRM met the primary efficacy endpoint demonstrating statistically significant improvement in total sleep time (TST) compared to placebo. Secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were met as well.
About Neurim Pharmaceuticals
Neurim Pharmaceuticals Ltd. (http://www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug Circadin® is commercially available in more than 45 countries around the world.
Neurim has a strong and innovative product pipeline, intended for insomnia, Alzheimer's disease, dementia, glaucoma and pain.
About Flynn Pharma
Flynn Pharma (http://www.flynnpharma.com) is a privately held speciality pharmaceutical company with interests in CNS medicine in adult and paediatric patient populations, supplying branded and generic medicines in the UK, Ireland and Germany and also through export. Flynn focuses on under-served patient populations by re-discovering and re-energising tried and trusted branded pharmaceutical products.
Dr. Hansjorg Jakubetz
Director Corporate Business Development
SOURCE Neurim Pharmaceuticals Ltd.